Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
about
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisInterferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosisGlatiramer acetate for multiple sclerosisIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineDimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisTreatment strategies for multiple sclerosis: When to start, when to change, when to stop?Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis.Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisManagement of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Current perspectives on interferon Beta-1b for the treatment of multiple sclerosisGlatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.Interferon β-1b and glatiramer acetate effects on permanent black hole evolutionInjectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis.Longitudinal changes in self-reported walking ability in multiple sclerosisOptimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisEffectiveness of glatiramer acetate compared to other multiple sclerosis therapiesComparison of standard 1.5 T vs. 3 T optimized protocols in patients treated with glatiramer acetate. A serial MRI pilot study.Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.Interferon beta and glatiramer acetate therapy.Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.Update on the treatment options for multiple sclerosis.Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.Principles of a new treatment algorithm in multiple sclerosis.Managing MS in a changing treatment landscape.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Management of children with multiple sclerosis.The management of pediatric multiple sclerosis.The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010
P2860
Q24187126-5E4E63E4-2ABE-4D24-9CF9-08E040839D1FQ24194800-589EB8C3-524F-4966-8F94-72CD001735C8Q24234763-398D27BB-AFB4-4051-BEC1-EC7AEFB4F27DQ24235498-8F7C1BB3-2186-4BAF-AB02-76087B4D3008Q24597369-78724133-4967-4D03-A36A-B10091F97ECBQ26752859-E7A707C2-4B94-44C3-ADBD-A0CE0E789942Q26777686-9DF1605B-858D-4ACE-B976-D56F4E4CAB28Q26798434-652F8B2F-6A87-40DA-9EE0-8167F8377828Q30882362-1ED300D4-65E1-4AB0-9FA5-9F6525FA6D7AQ33634866-8067B282-70D4-47E5-9EE9-207F89C1902CQ33755345-533865A0-3E1C-4829-9688-45EBBDE4B157Q33802186-95FC858F-A278-4067-8028-1BF40FBAEBB1Q33830080-888FFFB0-0C65-4EA6-9A1C-3255C33F7F1AQ33960392-417A2D6D-6B06-46C4-9855-DF2A9CC9C0EBQ34090086-63813247-5556-4AC0-9970-8577AC501C9DQ34253488-628F9AB9-E898-4023-971D-65D2E97C245BQ34473419-5DF51221-4B32-44CA-83A6-5A5466610496Q34743156-781CC260-BD15-442D-9080-610D16711622Q35557398-F4EC65C3-D6FE-4728-892F-E77D7460496AQ35560776-D1F6622E-F856-426C-8D30-56B990F47F17Q35588410-70D93F48-6114-4259-BA41-0116B98362CEQ35651621-06C17515-109D-41FA-99CB-2DCC4F0A0B2BQ35743570-527C4AA0-B831-43EF-A02D-FCF6D2ADA602Q36057186-355B2952-C372-446C-B3B8-C4E76CCCFEA9Q36202727-1C13A42C-0E8D-490C-8537-CC0F7CB4787CQ36568660-BDC16C80-F111-4E61-B79C-5C6DF8D96C2DQ36595213-A55F8E0E-0122-4A48-8B39-EA7D43DF2D7FQ36975701-D0BA016A-015B-4A5D-A475-A0BAC5D002C6Q37562166-8312923B-2991-405C-B830-004165A59DD5Q37729045-BDA2B953-7029-4E8E-A746-742937ACA7B2Q37732340-19081153-45C2-4E9B-A056-0F76F6A20934Q37849763-18236585-9240-4B75-9DA5-17EF4B36D4E3Q37857752-C28D4125-5561-4C80-868E-E87E0CDD1EBEQ37997089-00171543-C699-4501-9334-9DBCFA498587Q38002113-2A35677E-E8EB-4991-9F05-0435783957C8Q38036853-6C390EA7-34BD-4271-9325-5F13BEAD4565Q38116543-03EC5CC7-B894-40C5-8FDC-B3717EE3A220Q38152977-8594AA54-A4C5-42BC-B324-8CF3782CDC77Q38177871-DFB66562-9100-41BC-968C-DE66934620DCQ38181064-5276F0C9-D7B3-42DD-A610-895F21F388EA
P2860
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@en
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@nl
type
label
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@en
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@nl
prefLabel
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@en
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@nl
P2093
P1433
P1476
Efficacy of treatment of MS wi ...... brain MRI in the BECOME study.
@en
P2093
A R Pachner
J Cheriyan
J Skurnick
K Szczepanowski
L J Wolansky
P304
P356
10.1212/01.WNL.0000345970.73354.17
P407
P577
2009-03-11T00:00:00Z